There are 9 resources available
Welcome and Introduction
Presenter: M.J. Ahn, KR
Session: Welcome and Introduction
Resources:
Slides
Webcast
The structure, function and role of KRAS in normal cell homeostasis
Presenter: M. Barbacid, ES
Session: Session 1 – KRAS Biology, Epidemiology, Pathology
Resources:
Slides
Webcast
Molecular landscape of KRAS mutant NSCLC (molecular concomitant genetic alterations in KRAS mutant tumours)
Presenter: S.H. Lee, KR
Session: Session 1 – KRAS Biology, Epidemiology, Pathology
Resources:
Slides
Webcast
Pathology and molecular testing of NSCLC for KRAS mutations: who, how and when? (tissue, liquid biopsy)
Presenter: K. M. Kerr, UK
Session: Session 1 – KRAS Biology, Epidemiology, Pathology
Resources:
Slides
Webcast
Clinical development of KRAS G12C inhibitors – where are we now?
Presenter: Z. Li, CN
Session: Session 2 – Targeting KRAS G12C in Lung Cancer
Resources:
Slides
Webcast
Moving forward with KRAS G12C inhibitors – combinations (only chemotherapy and targeted therapy sequencing)
Presenter: F. Skoulidis, US
Session: Session 2 – Targeting KRAS G12C in Lung Cancer
Resources:
Slides
Webcast
Targeting KRAS beyond G12C – what is coming?
Presenter: H. R. Kim, KR
Session: Session 3 – Moving beyond KRAS G12C
Resources:
Slides
Webcast
Targeting KRAS with checkpoint inhibitors
Presenter: L. Mezquita, ES
Session: Session 3 – Moving beyond KRAS G12C
Resources:
Slides
Webcast
Vaccine and adoptive cell therapy strategies for the treatment of KRAS mutant NSCLC
Presenter: M. Nagasaka, US
Session: Session 3 – Moving beyond KRAS G12C
Resources:
Slides
Webcast